Affordable Access

deepdyve-link
Publisher Website

Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic.

Authors
  • Schultz, Émilien1
  • Mignot, Léo2
  • Ward, Jeremy K3
  • Boaventura Bomfim, Daniela4
  • Chabannon, Christian5
  • Mancini, Julien6
  • 1 Université Paris Cité, IRD, Ceped, 75006 Paris, France; SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, CANBIOS team (équipe labellisée LIGUE 2019), Aix-Marseille Université, Inserm, IRD, 13009 Marseille, France. Electronic address: [email protected] , (France)
  • 2 University of Bordeaux, CNRS, CED, UMR 5116, 33600 Pessac, France; Sciences Po Bordeaux, CNRS, CED, UMR 5116, 33600 Pessac, France. , (France)
  • 3 CERMES3, Inserm, CNRS, EHESS, Université de Paris Cité, 94801 Villejuif, France; VITROME, Aix-Marseille University, IRD, AP-HM, SSA, 13005 Marseille, France. , (France)
  • 4 University of Bordeaux, CNRS, CED, UMR 5116, 33600 Pessac, France; SIRIC BRIO, CHU de Bordeaux, Institut Bergonié, Université of Bordeaux, Inserm, CNRS, 33000 Bordeaux, France. , (France)
  • 5 Module Biothérapies du Centre d'Investigations Cliniques en Biothérapies, Inserm CBT-1409, Aix-Marseille Université, Institut Paoli-Calmettes comprehensive cancer center, 13005 Marseille, France. , (France)
  • 6 SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, CANBIOS team (équipe labellisée LIGUE 2019), Aix-Marseille Université, Inserm, IRD, 13009 Marseille, France; BioSTIC, AP-HM, Timone, 13005 Marseille, France. , (France)
Type
Published Article
Journal
Thérapie
Publisher
Elsevier
Publication Date
May 07, 2022
Identifiers
DOI: 10.1016/j.therap.2022.05.001
PMID: 35599194
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, public debates overtly addressed the promises of new innovative drugs. Many of these debates pitted those who advocated for the development of new drugs by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18-75years (n=1,000) during the second round of the "Health Literacy Survey 2019" (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the navigational health literacy score, OR 3.34 [2.13-5.24]). Respondents with a low level of trust in pharmaceutical companies or politicians were two times less likely to agree that new drugs are always more effective than old ones (OR 0.63 [0.42-0.95] and OR 0.68 [0.49-0.94], respectively). A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Our study shows that the perceived effectiveness of innovative drugs is associated with familiarity with the health care system and trust in institutions. Copyright © 2022 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times